Oncomine Comprehensive Panel with Tumor Mutation Burden and MSI Testing
Comprehensive Cancer Genomic Analysis for Personalized Treatment
The Oncomine Comprehensive Panel with Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) testing represents the pinnacle of modern cancer genomic diagnostics. This sophisticated multi-analyte test combines cutting-edge next-generation sequencing (NGS) technology with comprehensive biomarker analysis to provide clinicians with unprecedented insights into tumor biology and treatment opportunities.
What This Advanced Test Measures
This comprehensive panel evaluates three critical components of cancer genomics:
- Oncomine Comprehensive Panel: Analyzes over 500 cancer-related genes for mutations, amplifications, fusions, and copy number variations
- Tumor Mutation Burden (TMB): Quantifies the total number of mutations per megabase of DNA, a key predictor of immunotherapy response
- Microsatellite Instability (MSI): Detects defects in DNA mismatch repair, indicating potential responsiveness to immunotherapy and hereditary cancer syndromes
Who Should Consider This Comprehensive Testing
This advanced genomic testing is particularly valuable for patients with:
- Advanced or metastatic solid tumors requiring comprehensive genomic profiling
- Cancers with limited treatment options seeking immunotherapy eligibility assessment
- Patients with family history of cancer suggesting possible hereditary syndromes
- Individuals with rare or hard-to-treat cancers needing extensive biomarker analysis
- Patients considering clinical trial participation requiring comprehensive genomic data
Key Benefits of Comprehensive Genomic Profiling
This integrated testing approach offers multiple clinical advantages:
- Personalized Treatment Guidance: Identifies targeted therapy options based on specific genetic alterations
- Immunotherapy Prediction: TMB and MSI status help predict response to immune checkpoint inhibitors
- Hereditary Risk Assessment: MSI testing can indicate Lynch syndrome and other hereditary cancer predispositions
- Clinical Trial Matching: Comprehensive genomic data facilitates enrollment in appropriate clinical trials
- Treatment Resistance Monitoring: Helps identify mechanisms of resistance to current therapies
Understanding Your Test Results
Your comprehensive genomic report will include detailed information about:
- Actionable Mutations: Specific genetic alterations with approved targeted therapies
- TMB Classification: Low, intermediate, or high tumor mutation burden with immunotherapy implications
- MSI Status: Microsatellite stable (MSS) or unstable (MSI-H) with clinical significance
- Clinical Trial Recommendations: Potential trial opportunities based on genomic findings
- Hereditary Cancer Risk: Assessment of potential inherited cancer syndromes
Test Pricing and Sample Requirements
| Test Component | Price |
|---|---|
| Discount Price | $2626 USD |
| Regular Price | $3500 USD |
| Turnaround Time | 2-3 weeks |
| Sample Type | Tumor tissue + Peripheral Blood |
| Test Components | Paraffin embedded tissue blocks + EDTA Vacutainer (3 ml) |
| Testing Method | NGS + Sanger Sequencing |
Pre-Test Requirements
This comprehensive testing requires a doctor’s prescription for proper medical oversight. The prescription requirement ensures appropriate patient selection and clinical interpretation of results. Please note that prescription requirements do not apply to surgery and pregnancy cases or individuals planning international travel.
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our nationwide network ensures accessible comprehensive cancer genomic testing for patients throughout the country.
Take Control of Your Cancer Treatment Journey
Comprehensive genomic profiling represents a revolutionary approach to cancer care, providing critical information for personalized treatment decisions. The Oncomine Comprehensive Panel with TMB and MSI testing offers unparalleled insights into your cancer’s genetic makeup, potentially unlocking new treatment opportunities and improving clinical outcomes.
Ready to advance your cancer care with comprehensive genomic testing? Call or WhatsApp our dedicated oncology genetic specialists today at +1(267) 388-9828 to schedule your consultation and testing appointment. Our expert team is available to answer your questions and guide you through the testing process.
